#1451

Median 7-year outcomes of primary focal irreversible electroporation for localised prostate cancer

D. Feng¹, M. Scheltema¹, B. Geboers¹, A. Blazevski¹, S. Agrawal¹, J. Thompson¹, P. Stricker¹

¹St. Vincent's Prostate Cancer Research Centre, Sydney, Australia

Introduction:

To evaluate longer-term oncological and functional outcomes of focal irreversible electroporation (IRE) as primary treatment for localised clinically significant prostate cancer (csPCa) at a median follow-up of 7 years (up to 12 years).

Material and methods:

All patients that underwent focal IRE as primary treatment for localised PCa between February 2013 and February 2024 with a minimum 12 months of follow-up were analysed. Follow-up included 6-month magnetic resonance imaging (MRI) and standardised transperineal saturation template ± targeted biopsies at 12 months, and further biopsies in the case of clinical suspicion on serial imaging and/or prostate-specific antigen (PSA) levels. Failure-free survival (FFS) was defined as no progression to radical treatment or nodal/distant disease. Local recurrence was defined as any International Society of Urological Pathology Grade of ≥2 on biopsy.

Results:

A total of 376 patients were analysed with a median (interquartile range [IQR]) follow-up of 60 (40-80) months. The median (IQR) age was 67 (62-73) years, the median (IQR) PSA level was 5.8 (4.1-7.9) ng/mL. The clinically significant prostate cancer recurrent rate was 23.1% (87/376) overall. Of those patients, 0.3% (1/376) had active surveillance, and 9.6% (36/376) had a redo- IRE. In all, 63 patients progressed to radical treatment (16.8%) and overall failure free survival was 83.2%. PCa-specific survival was 100%. Continence and erectile function data is currently undergoing data analysis.